Background Onco-hematological patients are particularly susceptible to drug–drug
interactions (DDIs) because they often undergo multiple combined treatments. Some studies …

Background Frequently, haematological patients undergo highly complex and intensive
treatment protocols, so a high risk of drug–drug interactions could be expected. Objectives …

Background Oncological patients are at high risk for drug–drug interactions (DDIs), which
may contribute to therapeutic failure or lead to serious adverse events. Objective To …

Background Acquired haemophilia is an uncommon condition caused by the development
of clotting factor inhibitors. To eliminate them, immunosuppressive therapy with …

Background: Acquired haemophilia is an uncommon condition caused by the development
of clotting factor inhibitors. To eliminate them, immunosuppressive therapy with …

Background: Acquired haemophilia is an uncommon condition caused by the development
of clotting factor inhibitors. To eliminate them, immunosuppressive therapy with …

Background In Spain, the authorised indications for botulinum toxin type A (BTTA, Botox)
are: Neurological diseases: focal spasticity (foot, wrist and hand, ankle), blepharospasm …

Background Peginterferon–ribavirin treatment is the current standard of care for chronic
infection with hepatitis C virus. Boceprevir and telaprevir have been marketed as an …

Background The new protease inhibitors (PI) boceprevir and telaprevir have demonstrated
improved outcomes in hepatitis C virus (HCV)-infected patients in combination with …

Background Primary care pharmacists found an increase in osteoporosis drugs use and
expenditure. This concern was forwarded to the hospital management team, which …